Precision medicine is an approach to patient care that aims for the right intervention, in the right patient, at the right time – but what impact could this have on the treatment of infectious diseases? We asked Mathias Pletz about this approach to treatment, the research he’s directing at his institute and what the challenges are in this field.
Browsing: Molecular Diagnostics
A new rapid microelectrode device for the earlier diagnosis of sepsis has been developed by researchers at the University of Strathclyde.
Researchers from the Center for Infection and Immunity have made a major breakthrough in diagnoses of pathogenic bacteria with their design, the BacCapSeq platform. It’s the first precision medicine platform to allow simultaneous screening for all known bacterial pathogens, as well as markers for antibiotic resistance and virulence.
QIAGEN have announced the European launch of their next-generation platform for syndromic insights, QIAstat-Dx®, with data being presented at ECCMID demonstrating early success.
In this infographic we take a look at the diagnostics currently in the pipeline for tuberculosis, highlighting the stage of development and intended use.
A new test could extend the window for accurately detecting Zika virus, presenting a fast, cheap alternative.
Listen to the top stories in infectious diseases this week, including novel CRISPR-based diagnostics, clinical trial in tuberculosis and the latest CDC approvals for the flu vaccine.
The gene-editing technique CRISPR could be used to detect infections, potentially revolutionizing the detection of viruses such as HPV and Zika, according to two papers recently published in Science.
Recombinase polymerase amplification: a promising point-of-care detection method for enteric viruses
This report reviews the use of recombinase polymerase amplification for virus detection, showing that the method has favorable fundamental properties supporting its promise for rapid point-of-care detection of enteric viruses.
A new article has assessed the market penetration of a molecular TB test, Xpert MTB/RIF®, revealing that implementation in high-burden countries has progressed well, but there is more to be done.